Genvax Technologies, a startup dedicated to bringing advances in RNA vaccine production to animal health, announced it has closed its Series Seed Plus funding.
This pivotal funding will accelerate the company’s path toward USDA approval of its vaccines, enabling rapid response to foreign animal disease outbreaks and improving livestock health and profitability.
Genvax is a startup animal vaccine company located in Ames, Iowa, with a dynamic team of experienced scientists and entrepreneurs dedicated to developing next-generation RNA vaccines. Genvax offers an RNA platform that enables the rapid development of herd- or flock-specific vaccines matched precisely to the variant strain circulating in animal production operations. By inserting a specific transgene or “gene of interest” (GOI) matched to the variant strain into the platform, the RNA generates an antibody response without requiring the whole pathogen.
“The extraordinary threat of foreign animal diseases such as Highly Pathogenic Avian Influenza (HPAI), African Swine Fever (ASF), and evolving variants of swine influenza calls for groundbreaking solutions,” said Joel Harris, CEO and co-founder of Genvax Technologies. “For HPAI, our innovative vaccine could play a pivotal role in eradication efforts and strengthen global trade relationships.”